C2C_ASC
Autism Spectrum Disorder with Leaky Gut Syndrome
Key Facts
About Cell2Cure
Cell2Cure is a privately held, clinical-stage biotech based in Copenhagen, Denmark, founded in 2015 as a spinout from Rigshospitalet. The company has developed a proprietary GMP manufacturing process for its allogeneic adipose-derived MSC product, which has demonstrated a strong safety profile in over 300 patients across various indications. With a pipeline focused on inflammatory and autoimmune conditions, Cell2Cure operates through in-house development and strategic collaborations, positioning itself in the growing regenerative medicine market.
View full company profileAbout Cell2Cure
Cell2Cure is a privately held, clinical-stage biotech based in Copenhagen, Denmark, founded in 2015 as a spinout from Rigshospitalet. The company has developed a proprietary GMP manufacturing process for its allogeneic adipose-derived MSC product, which has demonstrated a strong safety profile in over 300 patients across various indications. With a pipeline focused on inflammatory and autoimmune conditions, Cell2Cure operates through in-house development and strategic collaborations, positioning itself in the growing regenerative medicine market.
View full company profileAbout Cell2Cure
Cell2Cure is a privately held, clinical-stage biotech based in Copenhagen, Denmark, founded in 2015 as a spinout from Rigshospitalet. The company has developed a proprietary GMP manufacturing process for its allogeneic adipose-derived MSC product, which has demonstrated a strong safety profile in over 300 patients across various indications. With a pipeline focused on inflammatory and autoimmune conditions, Cell2Cure operates through in-house development and strategic collaborations, positioning itself in the growing regenerative medicine market.
View full company profileAbout Cell2Cure
Cell2Cure is a privately held, clinical-stage biotech based in Copenhagen, Denmark, founded in 2015 as a spinout from Rigshospitalet. The company has developed a proprietary GMP manufacturing process for its allogeneic adipose-derived MSC product, which has demonstrated a strong safety profile in over 300 patients across various indications. With a pipeline focused on inflammatory and autoimmune conditions, Cell2Cure operates through in-house development and strategic collaborations, positioning itself in the growing regenerative medicine market.
View full company profileAbout Cell2Cure
Cell2Cure is a privately held, clinical-stage biotech based in Copenhagen, Denmark, founded in 2015 as a spinout from Rigshospitalet. The company has developed a proprietary GMP manufacturing process for its allogeneic adipose-derived MSC product, which has demonstrated a strong safety profile in over 300 patients across various indications. With a pipeline focused on inflammatory and autoimmune conditions, Cell2Cure operates through in-house development and strategic collaborations, positioning itself in the growing regenerative medicine market.
View full company profileAbout Cell2Cure
Cell2Cure is a privately held, clinical-stage biotech based in Copenhagen, Denmark, founded in 2015 as a spinout from Rigshospitalet. The company has developed a proprietary GMP manufacturing process for its allogeneic adipose-derived MSC product, which has demonstrated a strong safety profile in over 300 patients across various indications. With a pipeline focused on inflammatory and autoimmune conditions, Cell2Cure operates through in-house development and strategic collaborations, positioning itself in the growing regenerative medicine market.
View full company profile